Business Wire·Nov 11, 2026, 8:30 AM ET

Tempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting

Tempus AI will present six abstracts, including three oral presentations, at the 2026 Connective Tissue Oncology Society Annual Meeting in Seoul from November 18–21, 2026.
The research focuses on rare mesenchymal tumors & highlights how molecular diagnosis advances are unlocking new treatment options.
Findings leverage Tempus' multimodal library containing data from 45,085 real-world patients across 615 rare cancer types, with sarcomas being well-represented.
Clinical insights were derived using DNA matched tumor/normal sequencing, whole transcriptomic analysis, & digital pathology informatics.
Ezra Cohen, Chief Medical Officer of Oncology at Tempus, emphasized the value of the dataset for overcoming challenges in rare disease research & supporting the Orphan Disease Program.
Oral presentations on November 19, 2026, will cover MAGE-A4 mRNA expression & tumor immune micro-environment as biomarkers in sarcoma.
Oral presentations on November 20, 2026, will discuss a distinct DNA damage response transcriptional signature in SDH-deficient GIST & transcriptomic subtyping of 1,490 GIST patients.
Poster presentations will cover transcriptional programs associated with Pazopanib response, characteristics of desmoplastic small round cell tumor, & improved germline variant detection via matched sequencing.
Tempus AI is a technology company applying artificial intelligence to healthcare diagnostics & clinical workflows to enable personalized patient care.